UNASSIGNED: The study included 319 specimens collected over 12 months from 60 vaccinees aged 18 to 64. Binding antibodies were quantified using a validated ELISA method to measure SARS-CoV-2-specific IgG, IgM, and IgA levels against the S and N proteins.
UNASSIGNED: The results showed that baseline seropositivity for S-IgG was high at 67%, increasing to 98% by day 14 and consistently stayed above 95% for up to 12 months. However, S-IgM responses remained suboptimal. A raised S-IgA seropositivity rate was seen that doubled from 40% at baseline to 86% just two weeks following the initial vaccine dose, indicating sustained and robust peripheral immunity. An increase in N-IgG levels at nine months post-vaccination suggested breakthrough infections in eight cases. Baseline cross-reactivity influenced spike-directed antibody responses, with individuals harbouring S-IgG antibodies showing notably higher responses.
UNASSIGNED: Robust and long lasting vaccine and infection-induced immune responses were observed, with significant implications for regions where administering subsequent doses poses logistical challenges.
■该研究包括在12个月内从60名18至64岁的疫苗接种者中收集的319个样本。使用经过验证的ELISA方法对结合抗体进行定量,以测量SARS-CoV-2特异性IgG,IgM,和IgA水平对抗S和N蛋白。
■结果显示,S-IgG的基线血清阳性高达67%,到第14天增加到98%,并在长达12个月的时间里一直保持在95%以上。然而,S-IgM应答仍然是次优的。在初始疫苗剂量后两周,S-IgA血清阳性率升高,从基线时的40%增加到86%,表明持续和强大的外周免疫。疫苗接种后9个月N-IgG水平的增加表明8例患者发生突破性感染。基线交叉反应性影响尖峰定向抗体反应,携带S-IgG抗体的个体表现出明显更高的反应。
■观察到强健持久的疫苗和感染诱导的免疫反应,对后续剂量管理带来后勤挑战的地区有重大影响。